Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Camrelizumab by Jiangsu Hengrui Medicine for Nasopharyngeal Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Nasopharyngeal Cancer. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to...
Camrelizumab by Jiangsu Hengrui Medicine for Rectal Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Rectal Cancer. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...
Camrelizumab by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Human Epidermal Growth Factor Receptor...
Camrelizumab by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Metastatic Biliary Tract Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Metastatic Biliary Tract Cancer. According...
Camrelizumab by Jiangsu Hengrui Medicine for Follicular Lymphoma: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Follicular Lymphoma. According to GlobalData,...
Camrelizumab by Elevar Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
Camrelizumab is under clinical development by Elevar Therapeutics and currently in Pre-Registration for Hepatocellular Carcinoma. According to GlobalData, Pre-Registration drugs...
Camrelizumab by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...
Camrelizumab by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...